Bay Colony Advisory Group Inc d b a Bay Colony Advisors Buys New Stake in Alpha Teknova, Inc. (NASDAQ:TKNO)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Alpha Teknova, Inc. (NASDAQ:TKNO) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 21,614 shares of the company’s stock, valued at approximately $180,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of TKNO. China Universal Asset Management Co. Ltd. purchased a new stake in Alpha Teknova during the fourth quarter valued at approximately $94,000. Whalen Wealth Management Inc. purchased a new position in shares of Alpha Teknova in the fourth quarter worth $240,000. State Street Corp raised its holdings in shares of Alpha Teknova by 249.3% in the third quarter. State Street Corp now owns 76,645 shares of the company’s stock worth $371,000 after buying an additional 54,700 shares during the last quarter. Nkcfo LLC purchased a new position in shares of Alpha Teknova in the fourth quarter worth $501,000. Finally, Raymond James Financial Inc. purchased a new position in shares of Alpha Teknova in the fourth quarter worth $716,000. Hedge funds and other institutional investors own 13.81% of the company’s stock.

Alpha Teknova Trading Up 6.3 %

NASDAQ TKNO opened at $6.09 on Friday. The company has a fifty day simple moving average of $8.10 and a two-hundred day simple moving average of $6.90. The stock has a market cap of $324.65 million, a P/E ratio of -8.23 and a beta of 0.41. Alpha Teknova, Inc. has a 12-month low of $1.16 and a 12-month high of $10.37. The company has a current ratio of 4.73, a quick ratio of 3.94 and a debt-to-equity ratio of 0.12.

Alpha Teknova (NASDAQ:TKNO) last issued its earnings results on Tuesday, March 4th. The company reported ($0.11) earnings per share (EPS) for the quarter. Alpha Teknova had a negative return on equity of 35.30% and a negative net margin of 87.17%. The business had revenue of $9.27 million for the quarter, compared to analysts’ expectations of $9.10 million. On average, analysts forecast that Alpha Teknova, Inc. will post -0.58 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Craig Hallum initiated coverage on shares of Alpha Teknova in a report on Monday, February 10th. They issued a “buy” rating and a $12.00 price target for the company.

Alpha Teknova Profile

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.